Zobrazeno 1 - 10
of 645
pro vyhledávání: '"Siqing, Fu"'
Autor:
Sarina A. Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D. Karp, Vivek Subbiah, David Hong, Siqing Fu, Aung Naing, Jordi Rodon, Milind Javle, Jaffer A. Ajani, Kanwal P. Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric-Bernstam
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-14 (2024)
Abstract Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto
Externí odkaz:
https://doaj.org/article/1e0d0ae9bd434d9dbecfece7f428357b
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 1, Pp 41-52 (2024)
AT-rich interaction domain 1A (ARID1A), a mammalian switch/sucrose nonfermenting complex subunit, modulates several cellular processes by regulating chromatin accessibility. It is encoded by ARID1A, an immunosuppressive gene frequently disrupted in a
Externí odkaz:
https://doaj.org/article/bf87638e36ea48ff8560f9eee325db78
Autor:
Heather Lin, Vivek Subbiah, Siqing Fu, Aung Naing, Courtney Nicholas, Shubham Pant, Chad Tang, Michael A Curran, David S Hong, Ying Yuan, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timonthy A Yap, Apostolia M Tsimberidou, Daniel D Karp, Anupallavi Srinivasamani, Coline Couillault, Genevieve P Hartley, James Dai, Ecaterina E Ileana Dumbrava, Paola Guerrero, Sarah Dhebat, Theresa Proia
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective To evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3 antisense oligonucleotide (ASO) and checkpoint inhibition in conjunction with preclinical experi
Externí odkaz:
https://doaj.org/article/fd1c2105b438497dab4139b2a44f11d7
Autor:
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A. Piha‐Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric‐Bernstam, Aung Naing
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept is a recombinant fusion protein comprising human VEGF receptor extracellular domains fused to human immunoglobulin G1. HIF‐1α inhibition
Externí odkaz:
https://doaj.org/article/18bda712cd524278ae900d28a0907564
Autor:
Lei Zheng, Jun Gong, John Powderly, Tanios Bekaii-Saab, Angela Alistar, Siqing Fu, Nashat Gabrail, Dae Won Kim, Yvonne Saenger, Olatunji Alese, Apollina Goel, Nataliya Uboha, Laura Agensky, Matteo Levisetti, Steven Margossian, Steve Quayle, J Eva Selfridge, Jorge Chaves, Jin Zhaohui
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a058b50273b34e2ea776baa2cea44b42
Autor:
Omid Hamid, Siqing Fu, Manish Sharma, Anna Spreafico, Kyriakos P Papadopoulos, Erika Hamilton, Alexander Spira, Quincy Chu, Brigette Ma, Emily Roberts-Thomson, Dih-Yih Chen, Judy S Wang, Scott A Laurie, Mark R Bray, Roger Sidhu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b9d18b36b4844c1ab02ca1daf51708cf
Autor:
Siqing Fu, Rom S Leidner, Ki Chung, Jiaxin Niu, Ilian Tchakov, Debra L Richardson, Xiaoping Qing, Jorge Nieva, Douglas Adkins, Alan L Ho, Minh Phan, Alexander T Pearson, Marshall R Posner, Lisle Nabell, Stuart Wong, Katerin Rojas, Ari J Rosenberg, Trisha Kaufmann, Christopher Plescia, Corinne Iacobucci, Kia Katchar, Klaus Orlinger, Katia Schlienger, David G Pfister
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2139506c3af64695acf470195ba8dd75
Autor:
Vivek Subbiah, Huiying Sun, Siqing Fu, Lan Huang, Hui Gao, Steven H Lin, Ziyi Li, Evan Cohen, James Reuben, June Lu, Ken Lloyd, James Tonra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/736ba71af69449f78ebfab4a704dbae1
Autor:
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang, Apostolia M. Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A. Yap, David S. Hong, Ming Sun, Yunfang Jiang, Shubham Pant, Amishi Y. Shah, Amado Zurita, Nizar M. Tannir, Raghunandan Vikram, Jason Roszik, Funda Meric-Bernstam, Vivek Subbiah
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Pre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin a
Externí odkaz:
https://doaj.org/article/0e41dd980da3400cb70f16af34c1c22a
Autor:
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S. Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John V. Heymach, Funda Meric-Bernstam, Vivek Subbiah
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract Combined BRAF + MEK inhibition is FDA approved for BRAF V600E-mutant solid tumors except for colorectal cancer. However, beyond MAPK mediated resistance several other mechanisms of resistance such as activation of CRAF, ARAF, MET, P13K/AKT/m
Externí odkaz:
https://doaj.org/article/08c0964ed8d3474dbbdf8cf37ad472ba